Cover Image

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Edo J. Dongelmans, Milan J. Sonneveld
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
by: Yasuhito Tanaka, et al.
Published: (2026)

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
by: Ying‐Nan Tsai, et al.
Published: (2026)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
by: Hsiang‐Ting Keng, et al.
Published: (2026)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
by: Ming Chao Tsai, et al.
Published: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
by: Jian Wang, et al.
Published: (2025)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
by: Yuxin Chen, et al.
Published: (2024)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
by: Wen‐Juei Jeng, et al.
Published: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
by: Ying‐Nan Tsai, et al.
Published: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
by: Yuxin Chen, et al.
Published: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
by: Jian Wang, et al.
Published: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
by: Jian Wang, et al.
Published: (2024)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
by: Simon J. Hume, et al.
Published: (2025)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
by: Yen‐Chun Liu, et al.
Published: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
by: Hye Won Lee, et al.
Published: (2024)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
by: Xiaosong Li, et al.
Published: (2024)

Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy
by: Xiyao Chen, et al.
Published: (2024)

Letter: Muddle of serum sPD‐1 and sPD‐L1 levels and association with HBsAg clearance in HBeAg‐negative CHB patients on IFN therapy
by: Ankur Jindal
Published: (2024)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
by: Naohiro Yasuura, et al.
Published: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
by: Hsin‐Che Lin, et al.
Published: (2024)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
by: Lesley A. Patmore, et al.
Published: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
by: Yanxue Lin, et al.
Published: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
by: Tsutomu Nishida, et al.
Published: (2026)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
by: Xuwen Xu, et al.
Published: (2025)

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
by: Arno Furquim d’Almeida, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
by: Ersel Bilgin, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
by: Shiva Poola, et al.
Published: (2025)

Research Communication: Optimising Use of Stool Gluten Immunogenic Peptide Tests for Monitoring Adherence to Gluten‐Free Diet in Patients With Coeliac Disease
by: Juan P. Stefanolo, et al.
Published: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
by: Sarah Flatley
Published: (2026)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
by: Ellen Werner, et al.
Published: (2026)

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study
by: Raffaella Viganò, et al.
Published: (2025)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
by: María José Casanova, et al.
Published: (2025)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
by: Wei‐Fan Hsu, et al.
Published: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
by: Johan D. Söderholm
Published: (2025)

Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt
by: Michelle Spaan, et al.
Published: (2025)

Editorial: Carvedilol Remains the First‐Line Treatment of Portal Hypertension After the CALIBRE Trial
by: Thomas Reiberger, et al.
Published: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
by: Tyng‐Yuan Jang, et al.
Published: (2025)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
by: Laurent Lam, et al.
Published: (2024)